PL338457A1 - Sulphonylated dipeptidic compounds capable to inhibit adhesion of leucocytes through the mediation of vla-4 - Google Patents

Sulphonylated dipeptidic compounds capable to inhibit adhesion of leucocytes through the mediation of vla-4

Info

Publication number
PL338457A1
PL338457A1 PL98338457A PL33845798A PL338457A1 PL 338457 A1 PL338457 A1 PL 338457A1 PL 98338457 A PL98338457 A PL 98338457A PL 33845798 A PL33845798 A PL 33845798A PL 338457 A1 PL338457 A1 PL 338457A1
Authority
PL
Poland
Prior art keywords
dipeptidic
sulphonylated
leucocytes
vla
mediation
Prior art date
Application number
PL98338457A
Other languages
English (en)
Original Assignee
Elan Pharm Inc
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, American Home Prod filed Critical Elan Pharm Inc
Publication of PL338457A1 publication Critical patent/PL338457A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL98338457A 1997-07-31 1998-07-31 Sulphonylated dipeptidic compounds capable to inhibit adhesion of leucocytes through the mediation of vla-4 PL338457A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90442397A 1997-07-31 1997-07-31

Publications (1)

Publication Number Publication Date
PL338457A1 true PL338457A1 (en) 2000-11-06

Family

ID=25419137

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98338457A PL338457A1 (en) 1997-07-31 1998-07-31 Sulphonylated dipeptidic compounds capable to inhibit adhesion of leucocytes through the mediation of vla-4

Country Status (12)

Country Link
EP (1) EP0994896A1 (fr)
JP (1) JP2001512139A (fr)
KR (1) KR20010022405A (fr)
CN (1) CN1265672A (fr)
AU (1) AU8823498A (fr)
BR (1) BR9811594A (fr)
CA (1) CA2290748A1 (fr)
HU (1) HUP0003921A3 (fr)
IL (1) IL133637A0 (fr)
NO (1) NO20000452L (fr)
PL (1) PL338457A1 (fr)
WO (1) WO1999006437A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
WO1998054207A1 (fr) * 1997-05-30 1998-12-03 Celltech Therapeutics Limited Derives anti-inflammatoires de tyrosine
DK0991619T3 (da) 1997-06-23 2003-12-29 Tanabe Seiyaku Co Inhibitorer af alfa 4-beta 1-medieret celleadhæsion
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
ATE267168T1 (de) * 1997-11-24 2004-06-15 Merck & Co Inc Beta-alanin-derivate als zell-adhäsions- inhibitoren
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
EP1056714B1 (fr) 1998-02-26 2004-08-11 Celltech Therapeutics Limited Derives de phenylalanine en tant qu'inhibiteurs d'integrines alpha 4
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
US7396526B1 (en) 1998-11-12 2008-07-08 Johnson & Johnson Consumer Companies, Inc. Skin care composition
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
WO2000048994A1 (fr) * 1999-02-18 2000-08-24 F. Hoffmann-La Roche Ag Derives thioamides
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
EP1741428A3 (fr) * 1999-08-13 2007-05-09 Biogen Idec MA, Inc. inhibiteurs d'adhésion cellulaire
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
JP2003519697A (ja) 1999-12-28 2003-06-24 ファイザー・プロダクツ・インク 炎症性疾患、自己免疫疾患および呼吸器疾患の処置に有用な非ペプチド系のvla−4依存性細胞結合阻害薬
WO2001068586A2 (fr) * 2000-03-14 2001-09-20 Novartis Ag INHIBITEURS D'INTEGRINES α4β1 ET α4β¿7?
ATE375330T1 (de) 2000-04-17 2007-10-15 Ucb Pharma Sa Enamin-derivate als zell-adhäsionsmoleküle
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
JP2004502762A (ja) 2000-07-07 2004-01-29 セルテック アール アンド ディ リミテッド 二環性ヘテロ芳香環を含有するインテグリンアンタゴニストとしてのスクエア酸誘導体
AU2001275724A1 (en) 2000-08-02 2002-02-13 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
ATE497385T1 (de) 2000-08-18 2011-02-15 Ajinomoto Kk Neue phenylalanin-derivate
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
US6607735B2 (en) 2000-12-21 2003-08-19 Johnson & Johnson Consumer Companies, Inc. Method for reducing the appearance of dark circles under the eyes
JP2004526733A (ja) 2001-03-20 2004-09-02 メルク エンド カムパニー インコーポレーテッド 強力な細胞接着阻害剤としての置換n−アリールスルホニル−プロリン誘導体
US6559174B2 (en) 2001-03-20 2003-05-06 Merck & Co., Inc. N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
US6855708B2 (en) 2001-03-20 2005-02-15 Merck & Co., Inc. N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors
EP1477482B1 (fr) * 2002-02-20 2010-04-14 Ajinomoto Co., Inc. Nouveau derive de phenylalanine
EP1592386A4 (fr) * 2003-01-24 2007-06-13 Elan Pharm Inc Composition et methode destinees a traiter les maladies de demyelinisation et la paralysie par administration d'agents de remyelinisation
UY28391A1 (es) * 2003-06-25 2004-12-31 Elan Pharm Inc Metodos y composiciones para tratar artritis reumatoide
EP1683525B1 (fr) * 2003-11-14 2017-05-17 EA Pharma Co., Ltd. Preparation de derives de phenylalanine a liberation soutenue pour une administration orale
ES2360064T3 (es) * 2003-11-14 2011-05-31 Ajinomoto Co., Inc. Dispersión sólida o preparación de dispersión sólida medicinal de un derivado de fenilalanina.
EP1968635B1 (fr) * 2005-12-14 2014-09-17 Ambrx, Inc. Compositions contenant des acides aminés et polypeptides non naturels, procédés mettant en jeu ceux-ci et utilisations de ceux-ci
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
CA2721093A1 (fr) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Lieurs d'albumine de serum humain, et ses conjugues
JP6007417B2 (ja) 2011-05-31 2016-10-12 レセプトス エルエルシー 新規glp−1受容体安定剤および調節剤
AU2012352349B2 (en) * 2011-12-12 2017-08-17 Receptos Llc Carboxylic acid derivatives comprising four cycles acting as GLP-1 receptor modulators for therapy of diseases such as diabetes
KR102271179B1 (ko) 2013-06-11 2021-07-01 셀진 인터내셔널 Ii 에스에이알엘 신규의 glp-1 수용체 조절제
MX2017000972A (es) 2014-07-25 2017-07-27 Celgene Int Ii Sarl Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1).
WO2016094729A1 (fr) 2014-12-10 2016-06-16 Celgene International Ii Sarl Nouveaux modulateurs du récepteur du glp-1
US10308677B2 (en) * 2014-12-19 2019-06-04 Cem Corporation Coupling method for peptide synthesis at elevated temperatures
US9969769B2 (en) 2014-12-19 2018-05-15 Cem Corporation Coupling method for peptide synthesis at elevated temperatures
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ, インコーポレイテッド アルファ4β7インテグリンの阻害のための化合物
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ, インコーポレイテッド アルファ4ベータ7インテグリンの阻害のための化合物
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ, インコーポレイテッド アルファ4ベータ7インテグリン阻害剤としてのイミダゾピリジン誘導体
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2679903B1 (fr) * 1991-08-02 1993-12-03 Elf Sanofi Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
JPH04154732A (ja) * 1990-10-18 1992-05-27 Nippon Kayaku Co Ltd 光学分割法
WO1994007815A2 (fr) * 1992-09-25 1994-04-14 Abbott Laboratories Ligands du recepteur du petit peptide anaphylatoxine
US5648368A (en) * 1992-12-01 1997-07-15 Merck & Co., Inc. Fibrinogen receptor antagonists
AU693143B2 (en) * 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
JPH0873422A (ja) * 1994-09-07 1996-03-19 Kdk Corp 新規アミノ酸エステルおよび白血球、エステラーゼ又はプロテアーゼの検出方法
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors

Also Published As

Publication number Publication date
IL133637A0 (en) 2001-04-30
BR9811594A (pt) 2000-09-05
KR20010022405A (ko) 2001-03-15
HUP0003921A2 (hu) 2001-02-28
EP0994896A1 (fr) 2000-04-26
WO1999006437A1 (fr) 1999-02-11
CA2290748A1 (fr) 1999-02-11
JP2001512139A (ja) 2001-08-21
NO20000452D0 (no) 2000-01-28
AU8823498A (en) 1999-02-22
NO20000452L (no) 2000-03-27
CN1265672A (zh) 2000-09-06
HUP0003921A3 (en) 2001-03-28

Similar Documents

Publication Publication Date Title
PL338457A1 (en) Sulphonylated dipeptidic compounds capable to inhibit adhesion of leucocytes through the mediation of vla-4
PL338554A1 (en) Dipeptidic compounds inhibiting adhesion of leucocytes occurring through the mediation of vla-4
PL338521A1 (en) Carbamyloxylic compounds inhibiting adhesion of leucocytes occurring through the mediation of vla-4
PL338423A1 (en) Compounds of substituted phenylamine type capable to inhibit adhesion of leucocytes through the mediation of vla-4
PL338506A1 (en) Compounds inhibiting adhesion of leucocytes occuring through the mediation of vla-4
PL338510A1 (en) Benzyl compounds inhinbiting the adhesion of leucocytes occurring through the mediation of vla-4
PL338413A1 (en) Compound of 4-amino phenylalanine type inhibiting adhesion of leucocytes through the meditation of vla-4
PL338373A1 (en) Dipeptide and its affinite compounds inhibiting adhesion of leucocytes occurring through mediation of vla-4
IL127563A0 (en) Cell adhesion inhibiting compounds
AU5609998A (en) Tablet for the controlled release of active agents
AU1208999A (en) Compounds which inhibit tryptase activity
AU7292398A (en) Antithrombotic compound
IL130957A0 (en) Absorbent article with improved dual fastening system
GB2341180A9 (en) Compounds on the basis of polyalkyl-1-oxa diazaspirodecane compounds
AU752953C (en) Adding pharmaceutically active compounds to substrates
GB9724982D0 (en) The biker back brake
HUP0002719A3 (en) Controlled release pharmaceutical preparation with ace inhibitor as active agent
AU1301299A (en) Compounds which inhibit tryptase activity
AP9600857A0 (en) Pharmacologically active compound
ZA963849B (en) Active compound combinations
AU8532798A (en) Compounds which delay the release of active substances
AU1786799A (en) Composition for the controlled release of active compounds
AU7522898A (en) Pseudo-peptide compounds as antagonists of neurokinines
AU5567798A (en) Improvements relating to rack storage systems
GB9711118D0 (en) Compound

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)